NASDAQ:CSII

Cardiovascular Systems Stock Forecast, Price & News

$40.72
+0.67 (+1.67 %)
(As of 06/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$39.82
$40.78
50-Day Range
$34.41
$40.97
52-Week Range
$27.70
$48.28
Volume107,269 shs
Average Volume205,729 shs
Market Capitalization$1.64 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.85
30 days | 90 days | 365 days | Advanced Chart
Receive CSII News and Ratings via Email

Sign-up to receive the latest news and ratings for Cardiovascular Systems and its competitors with MarketBeat's FREE daily newsletter.


Cardiovascular Systems logo

About Cardiovascular Systems

Cardiovascular Systems, Inc., a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company has a partnership with Chansu Vascular Technologies, LLC to develop novel peripheral and coronary everolimus drug-coated balloons. Cardiovascular Systems, Inc. was founded in 1989 and is headquartered in St. Paul, Minnesota.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.63 out of 5 stars

Medical Sector

414th out of 2,102 stocks

Surgical & Medical Instruments Industry

38th out of 174 stocks

Analyst Opinion: 2.4Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Cardiovascular Systems (NASDAQ:CSII) Frequently Asked Questions

Is Cardiovascular Systems a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cardiovascular Systems in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Cardiovascular Systems stock.
View analyst ratings for Cardiovascular Systems
or view top-rated stocks.

What stocks does MarketBeat like better than Cardiovascular Systems?

Wall Street analysts have given Cardiovascular Systems a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cardiovascular Systems wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Cardiovascular Systems' next earnings date?

Cardiovascular Systems is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Cardiovascular Systems
.

How were Cardiovascular Systems' earnings last quarter?

Cardiovascular Systems, Inc. (NASDAQ:CSII) announced its earnings results on Thursday, May, 6th. The medical device company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.05. The medical device company had revenue of $63.30 million for the quarter, compared to analyst estimates of $63.18 million. Cardiovascular Systems had a negative trailing twelve-month return on equity of 8.62% and a negative net margin of 10.11%. The business's revenue for the quarter was up 3.4% on a year-over-year basis. During the same quarter last year, the firm posted ($0.08) EPS.
View Cardiovascular Systems' earnings history
.

How has Cardiovascular Systems' stock price been impacted by COVID-19?

Cardiovascular Systems' stock was trading at $36.32 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, CSII shares have increased by 12.1% and is now trading at $40.72.
View which stocks have been most impacted by COVID-19
.

What guidance has Cardiovascular Systems issued on next quarter's earnings?

Cardiovascular Systems issued an update on its fourth quarter 2021 earnings guidance on Thursday, May, 27th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $67 million-$70 million, compared to the consensus revenue estimate of $69.78 million.

What price target have analysts set for CSII?

6 brokerages have issued 12-month target prices for Cardiovascular Systems' stock. Their forecasts range from $43.00 to $50.00. On average, they expect Cardiovascular Systems' stock price to reach $47.17 in the next twelve months. This suggests a possible upside of 15.8% from the stock's current price.
View analysts' price targets for Cardiovascular Systems
or view top-rated stocks among Wall Street analysts.

Who are Cardiovascular Systems' key executives?

Cardiovascular Systems' management team includes the following people:
  • Mr. Scott Raymond Ward M.S., MS, B.Sc., Chairman, Pres & CEO (Age 61, Pay $1.17M)
  • Mr. Jeffrey S. Points, Chief Financial Officer (Age 44, Pay $507.49k)
  • Ms. Rhonda J. Robb, Chief Operating Officer (Age 53, Pay $830.22k)
  • Mr. Alexander Rosenstein, Gen. Counsel & Corp. Sec. (Age 49, Pay $523.26k)
  • Dr. Ryan D. Egeland M.D., Ph.D., Chief Medical Officer (Age 46, Pay $490.64k)
  • Mr. John E. Nielsen, VP of Investor Relations & Corp. Communications
  • Ms. Sandra M. Sedo, Chief Compliance Officer (Age 57)
  • Mr. David S. Whitescarver, VP of Corp. Devel. & Intellectual Property (Age 63)
  • Mr. Stephen J. Rempe, Chief HR Officer (Age 48)

What is Scott Ward's approval rating as Cardiovascular Systems' CEO?

12 employees have rated Cardiovascular Systems CEO Scott Ward on Glassdoor.com. Scott Ward has an approval rating of 81% among Cardiovascular Systems' employees.

Who are some of Cardiovascular Systems' key competitors?

What other stocks do shareholders of Cardiovascular Systems own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cardiovascular Systems investors own include Gilead Sciences (GILD), AbbVie (ABBV), Advanced Micro Devices (AMD), Medtronic (MDT), Pfizer (PFE), (XEL), ACADIA Pharmaceuticals (ACAD), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and The Procter & Gamble (PG).

What is Cardiovascular Systems' stock symbol?

Cardiovascular Systems trades on the NASDAQ under the ticker symbol "CSII."

Who are Cardiovascular Systems' major shareholders?

Cardiovascular Systems' stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (17.68%), Brown Capital Management LLC (14.95%), Champlain Investment Partners LLC (8.59%), RGM Capital LLC (4.04%), Janus Henderson Group PLC (3.41%) and Renaissance Technologies LLC (2.76%). Company insiders that own Cardiovascular Systems stock include Alexander Rosenstein, Erik Paulsen, Martha Goldberg Aronson, Rhonda J Robb, Sandra Sedo and Scott R Ward.
View institutional ownership trends for Cardiovascular Systems
.

Which institutional investors are selling Cardiovascular Systems stock?

CSII stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, Nuveen Asset Management LLC, Northern Trust Corp, Gamco Investors INC. ET AL, Bank of Montreal Can, Citigroup Inc., and AQR Capital Management LLC. Company insiders that have sold Cardiovascular Systems company stock in the last year include Alexander Rosenstein, and Sandra Sedo.
View insider buying and selling activity for Cardiovascular Systems
or view top insider-selling stocks.

Which institutional investors are buying Cardiovascular Systems stock?

CSII stock was acquired by a variety of institutional investors in the last quarter, including RGM Capital LLC, Champlain Investment Partners LLC, Dimensional Fund Advisors LP, BlackRock Inc., JPMorgan Chase & Co., Victory Capital Management Inc., Geode Capital Management LLC, and GW&K Investment Management LLC. Company insiders that have bought Cardiovascular Systems stock in the last two years include Erik Paulsen, Martha Goldberg Aronson, Rhonda J Robb, and Scott R Ward.
View insider buying and selling activity for Cardiovascular Systems
or or view top insider-buying stocks.

How do I buy shares of Cardiovascular Systems?

Shares of CSII can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cardiovascular Systems' stock price today?

One share of CSII stock can currently be purchased for approximately $40.72.

How much money does Cardiovascular Systems make?

Cardiovascular Systems has a market capitalization of $1.64 billion and generates $236.54 million in revenue each year. The medical device company earns $-27,240,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

How many employees does Cardiovascular Systems have?

Cardiovascular Systems employs 779 workers across the globe.

What is Cardiovascular Systems' official website?

The official website for Cardiovascular Systems is www.csi360.com.

Where are Cardiovascular Systems' headquarters?

Cardiovascular Systems is headquartered at 1225 OLD HWY 8 NW, ST. PAUL MN, 55112.

How can I contact Cardiovascular Systems?

Cardiovascular Systems' mailing address is 1225 OLD HWY 8 NW, ST. PAUL MN, 55112. The medical device company can be reached via phone at 651-259-1600 or via email at [email protected]


This page was last updated on 6/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.